AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have earned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $19.3333.

A number of research firms have recently issued reports on ANGO. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. Wall Street Zen downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Finally, Zacks Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 9th.

Institutional Investors Weigh In On AngioDynamics

A number of institutional investors have recently added to or reduced their stakes in ANGO. Divisadero Street Capital Management LP raised its holdings in shares of AngioDynamics by 253.7% in the 2nd quarter. Divisadero Street Capital Management LP now owns 3,395,430 shares of the medical instruments supplier’s stock worth $33,683,000 after buying an additional 2,435,365 shares in the last quarter. Weber Capital Management LLC ADV acquired a new position in AngioDynamics during the fourth quarter worth $17,978,000. UBS Group AG raised its stake in AngioDynamics by 83.6% during the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after acquiring an additional 501,881 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after acquiring an additional 393,682 shares during the period. Finally, Bastion Asset Management Inc. boosted its stake in shares of AngioDynamics by 31.8% in the 3rd quarter. Bastion Asset Management Inc. now owns 1,264,003 shares of the medical instruments supplier’s stock valued at $13,442,000 after purchasing an additional 304,960 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Stock Performance

Shares of ANGO opened at $10.56 on Friday. The company has a 50-day simple moving average of $11.86 and a 200-day simple moving average of $11.13. AngioDynamics has a 52 week low of $8.27 and a 52 week high of $13.99. The firm has a market capitalization of $435.28 million, a P/E ratio of -15.76 and a beta of 0.51.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.